Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer

  • Authors:
    • Lee Cheng Phua
    • Hui Wen Ng
    • Angie Hui Ling Yeo
    • Elya Chen
    • Michelle Shu Mei Lo
    • Peh Yean Cheah
    • Eric Chun Yong Chan
    • Poh Koon Koh
    • Han Kiat Ho
  • View Affiliations

  • Published online on: August 3, 2015     https://doi.org/10.3892/ol.2015.3560
  • Pages: 2519-2526
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Mutations in oncogenes along the epidermal growth factor receptor (EGFR) signaling pathway have been implicated in the resistance to cetuximab in patients with metastatic colorectal cancer (mCRC). However, the relative significance of these mutations based on their frequencies of occurrence in the Singaporean population remains unclear. In the present study, the prevalence of Kirsten rat sarcoma viral oncogene homolog (KRAS), v‑Raf murine sarcoma viral oncogene homolog B (BRAF), phosphoinositide 3‑kinase (PI3K) and EGFR somatic mutations were determined among Singaporean patients with mCRC. DNA extracted from 45 pairs of surgically resected tumor and normal mucosa samples was subjected to direct sequencing or restriction fragment length polymorphism. Associations of the genetic mutations with various clinicopathological parameters were further explored. Mutations in either codon 12 or 13 of KRAS were confirmed as prominent phenomena among the included Singaporean mCRC patients, at a prevalence comparable with that of Caucasian and patients of other Asian ethnicities [33.3% (90% confidence interval, 21.8‑44.9%)]. KRAS mutation was not associated with clinicopathological features, including age, gender and ethnicity of patients, or the tumor site, differentiation and mucinous status. Conversely, the prevalence of BRAF (0%), PI3K (2.2%) and EGFR (0%) mutations were low. The results of the present study indicate that KRAS mutations are prevalent among the studied population, and confirm the low prevalence of BRAF, PI3K and EGFR mutations. KRAS should be prioritized as an investigational gene for future studies of predictive biomarkers of cetuximab response among Singaporean patients with mCRC.

References

1 

Sung JJ, Lau JY, Goh KL and Leung WK: Asia Pacific Working Group on Colorectal Cancer: Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 6:871–876. 2005. View Article : Google Scholar : PubMed/NCBI

2 

Singapore cancer registry interim report, . Trends in cancer incidence in Singapore 2007–2011National Registry of Diseases Office (NRDO). Health Promotion Board; Singapore: 2011

3 

Vecchione L, Jacobs B, Normanno N, et al: EGFR-targeted therapy. Exp Cell Res. 317:2765–2771. 2011. View Article : Google Scholar : PubMed/NCBI

4 

Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med. 357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI

5 

Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI

6 

Saltz LB, Meropol NJ, Loehrer PJ Sr, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 22:1201–1208. 2004. View Article : Google Scholar : PubMed/NCBI

7 

Karapetis CS, KhambataFord S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI

8 

VanCutsem E, Lang I, D'haens G, et al: Kras status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mcrc) treated with folfiri with or without cetuximab: The crystal experience. J Clin Oncol, 2008 ASCO Annual Meeting Proceedings. 26:22008.

9 

VanCutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011. View Article : Google Scholar : PubMed/NCBI

10 

Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, Nippgen J, Stroh C, Celik I and Koralewski P: Kras status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mcrc) with folfox with or without cetuximab: The opus experience. J Clin Oncol. 26 (Suppl 4000):2008.

11 

Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M and Koralewski P: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol. 22:1535–1546. 2011. View Article : Google Scholar : PubMed/NCBI

12 

Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 27:2091–2096. 2009. View Article : Google Scholar : PubMed/NCBI

13 

U.S. Food and Drug Administration, . Class labeling changes to anti-EGFR monoclonal antibodies, cetuximab (erbitux) and panitumumab (vectibix). Kras mutations. 2009.simplehttp://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm172905.htmAccessed July 15 2013.

14 

LaurentPuig P, Cayre A, Manceau G, et al: Analysis of PTEN, BRAF and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 27:5924–5930. 2009. View Article : Google Scholar : PubMed/NCBI

15 

DeRoock W, Claes B, Bernasconi D, et al: Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010. View Article : Google Scholar : PubMed/NCBI

16 

Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004. View Article : Google Scholar : PubMed/NCBI

17 

Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI

18 

Eck MJ and Yun CH: Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta. 1804:559–566. 2010. View Article : Google Scholar : PubMed/NCBI

19 

Takano T, Ohe Y, Sakamoto H, et al: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 23:6829–6837. 2005. View Article : Google Scholar : PubMed/NCBI

20 

Gao J, Wang TT, Yu JW, Li YY and Shen L: Wild-type kras and braf could predict response to cetuximab in chinese colorectal cancer patients. Chin J Cancer Res. 23:271–275. 2011. View Article : Google Scholar : PubMed/NCBI

21 

Li FH, Shen L, Li ZH, Luo HY, Qiu MZ, Zhang HZ, Li YH and Xu RH: Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. World J Gastroenterol. 16:5881–5888. 2010. View Article : Google Scholar : PubMed/NCBI

22 

Mao C, Zhou J, Yang Z, Huang Y, Wu X, Shen H, Tang J and Chen Q: KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS One. 7:e366532012. View Article : Google Scholar : PubMed/NCBI

23 

Kato S, Iida S, Higuchi T, Ishikawa T, Takagi Y, Yasuno M, Enomoto M, Uetake H and Sugihara K: PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer. 121:1771–1778. 2007. View Article : Google Scholar : PubMed/NCBI

24 

Kimura T, Okamoto K, Miyamoto H, et al: Clinical benefit of high-sensitivity KRAS mutation testing in metastatic colorectal cancer treated with anti-EGFR antibody therapy. Oncology. 82:298–304. 2012. View Article : Google Scholar : PubMed/NCBI

25 

Ito Y, Yamada Y, Asada K, Ushijima T, Iwasa S, Kato K, Hamaguchi T and Shimada Y: EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients. J Cancer Res Clin Oncol. 139:1391–1396. 2013. View Article : Google Scholar : PubMed/NCBI

26 

Nakanishi R, Harada J, Tuul M, Zhao Y, Ando K, Saeki H, Oki E, Ohga T, Kitao H, Kakeji Y and Maehara Y: Prognostic relevance of KRAS and BRAF mutations in japanese patients with colorectal cancer. Int J Clin Oncol. 18:1042–1048. 2013. View Article : Google Scholar : PubMed/NCBI

27 

Pang NK, Nga ME, Chin SY, Ismail TM, Lim GL, Soong R and Salto-Tellez M: KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma. Cytopathology. 22:358–364. 2011. View Article : Google Scholar : PubMed/NCBI

28 

Moroni M, Veronese S, Benvenuti S, Marrapese G, SartoreBianchi A, Di Nicolantonio F, Gambacorta M, Siena S and Bardelli A: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol. 6:279–286. 2005. View Article : Google Scholar : PubMed/NCBI

29 

Brevet M, Johnson ML, Azzoli CG and Ladanyi M: Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer. 73:96–102. 2011. View Article : Google Scholar : PubMed/NCBI

30 

Ruhe JE, Streit S, Hart S, et al: Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res. 67:11368–11376. 2007. View Article : Google Scholar : PubMed/NCBI

31 

DiNicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 26:5705–5712. 2008. View Article : Google Scholar : PubMed/NCBI

32 

Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F and Mazzucchelli L: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer. 97:1139–1145. 2007. View Article : Google Scholar : PubMed/NCBI

33 

Molinari F, Felicioni L, Buscarino M, et al: Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res. 17:4901–4914. 2011. View Article : Google Scholar : PubMed/NCBI

34 

Lièvre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66:3992–3995. 2006. View Article : Google Scholar : PubMed/NCBI

35 

Heinemann V, Stintzing S, Kirchner T, Boeck S and Jung A: Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev. 35:262–271. 2009. View Article : Google Scholar : PubMed/NCBI

36 

Zlobec I, Bihl MP, Schwarb H, Terracciano L and Lugli A: Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Intl J Cancer. 127:367–380. 2010.

37 

Chaiyapan W, Duangpakdee P, Boonpipattanapong T, Kanngern S and Sangkhathat S: Somatic mutations of K-ras and BRAF in Thai colorectal cancer and their prognostic value. Asian Pac J Cancer Prev. 14:329–332. 2013. View Article : Google Scholar : PubMed/NCBI

38 

Wu CM, Tang R, Wang JY, Changchien CR and Hsieh LL: Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan. Cancer Genet Cytogenet. 158:55–60. 2005. View Article : Google Scholar : PubMed/NCBI

39 

Kim ST, Park KH, Kim JS, Shin SW and Kim YH: Impact of kras mutation status on outcomes in metastatic colon cancer patients without anti-epidermal growth factor receptor therapy. Cancer Res Treat. 45:55–62. 2013. View Article : Google Scholar : PubMed/NCBI

40 

Gallimore AM and Godkin A: Epithelial barriers, microbiota and colorectal cancer. N Engl J Med. 368:282–284. 2013. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2015
Volume 10 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Phua, L.C., Ng, H.W., Yeo, A.H., Chen, E., Lo, M.S., Cheah, P.Y. ... Ho, H.K. (2015). Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer. Oncology Letters, 10, 2519-2526. https://doi.org/10.3892/ol.2015.3560
MLA
Phua, L. C., Ng, H. W., Yeo, A. H., Chen, E., Lo, M. S., Cheah, P. Y., Chan, E. C., Koh, P. K., Ho, H. K."Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer". Oncology Letters 10.4 (2015): 2519-2526.
Chicago
Phua, L. C., Ng, H. W., Yeo, A. H., Chen, E., Lo, M. S., Cheah, P. Y., Chan, E. C., Koh, P. K., Ho, H. K."Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer". Oncology Letters 10, no. 4 (2015): 2519-2526. https://doi.org/10.3892/ol.2015.3560